g., NKG2D ligands (172), CD38 (173), CD123 (174), NPM1c (175), CD7 (176), etc.] have shown preclinical efficacy in hematological malignancies and are being investigated in clinical trials for AML. This evidence concerns the gene CD38 and acute myeloid leukemia.